Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
Ajouter des filtres








Gamme d'année
1.
China Pharmacy ; (12)2001.
Article Dans Chinois | WPRIM | ID: wpr-528018

Résumé

OBJECTIVE:To discuss the necessity of clearing the pharmaceutical butyl rubber stoppers for infusion bottles before use.METHODS:Pharmaceutical butyl rubber stoppers for infusion bottles produced by manufacturer A and B were se-lected and washed at least once before a preliminary test was performed.Then product A was chosen for further test.The stoppers of two different batch numbers by manufacturer A were selected,one washed with injecting water and another not washed,all of which were used in the production of all kinds of transfusions in the hospital where the authors worked,then infusible motes in these products were measured.RESULTS:The infusible motes in the products with unwashed stoppers was not in accordance with the requirements in China Pharmacopoeia,while those with washed ones was in accordance.CONCLU_ SION:The pharmaceutical butyl rubber stoppers for infusion bottles must be washed by injecting water at least once before use to ensure the quality of the products.

2.
China Pharmacy ; (12)1991.
Article Dans Chinois | WPRIM | ID: wpr-527033

Résumé

OBJECTIVE:To study the cost-effectiveness of4dose regimens in treating chronic prostatitis/chronic pelvic cavity pain syndrome(CP/CPPS).METHODS:A total of140patients with CP/CPPS were randomly divided into4groups:Baiyanjing tablets and tamsulosin hydrochloride modified release capsules were administered for Group A;minocycline micro pills and alfuzosin retard tablets for Group B;rexithromycin tablets and doxazosin mesylate controlled release tablets for Group C;and levofloxacin tablets and terazosin tablets for Group D.The cost-effectiveness analysis was performed using pharma?coeconomics.RESULTS:The costs for the Group A,B,C and D were268.8yuan,641.8yuan,660.8yuan and666.4yuan,respectively.The effective rates were71.4%,91.4%,88.6%and91.4%,respectively.The cost-effectiveness ratios were3.76,7.02,7.46and7.29,respectively.The incremental cost-effectiveness ratios of Group B,C and D were18.65,22.79and19.88,respectively as against Group A.CONCLUSION:The treatment cost of CP/CPPS was composed of2parts:an?tibiotics? 1 -receptor blockers.Doctors should make an optimum choice based on patients'previous medication,economic status and physical condition,etc.

SÉLECTION CITATIONS
Détails de la recherche